Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Prime Medicine Inc (NASDAQ: PRME) was $6.67 for the day, up 19.32% from the previous closing price of $5.59. In other words, the price has increased by $19.32 from its previous closing price. On the day, 5.61 million shares were traded. PRME stock price reached its highest trading level at $6.7 during the session, while it also had its lowest trading level at $5.615.
Ratios:
Our analysis of PRME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.56 and its Current Ratio is at 3.56. In the meantime, Its Debt-to-Equity ratio is 1.97 whereas as Long-Term Debt/Eq ratio is at 1.85.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 01 ’25 when GV 2021 GP, L.L.C. bought 1,500,000 shares for $3.30 per share. The transaction valued at 4,950,000 led to the insider holds 3,262,440 shares of the business.
NELSEN ROBERT bought 3,030,300 shares of PRME for $9,999,990 on Aug 01 ’25. The Director now owns 6,230,300 shares after completing the transaction at $3.30 per share. On Aug 01 ’25, another insider, ARCH Venture Partners XII, LLC, who serves as the 10% Owner of the company, bought 3,030,300 shares for $3.30 each. As a result, the insider paid 9,999,990 and bolstered with 6,230,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 1189087616 and an Enterprise Value of 892432704. For the stock, the TTM Price-to-Sale (P/S) ratio is 239.63 while its Price-to-Book (P/B) ratio in mrq is 14.74. Its current Enterprise Value per Revenue stands at 179.89 whereas that against EBITDA is -4.521.
Stock Price History:
The Beta on a monthly basis for PRME is 2.66, which has changed by 0.9002849 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $5.82, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 61.15%, while the 200-Day Moving Average is calculated to be 140.33%.
Shares Statistics:
PRME traded an average of 4.23M shares per day over the past three months and 3653370 shares per day over the past ten days. A total of 134.49M shares are outstanding, with a floating share count of 91.65M. Insiders hold about 48.57% of the company’s shares, while institutions hold 22.11% stake in the company. Shares short for PRME as of 1757894400 were 19119429 with a Short Ratio of 4.51, compared to 1755216000 on 18372361. Therefore, it implies a Short% of Shares Outstanding of 19119429 and a Short% of Float of 17.629998999999998.
Earnings Estimates
At present, 10.0 analysts are actively evaluating the performance of Prime Medicine Inc (PRME) in the stock market.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.11 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.06 and -$1.45 for the fiscal current year, implying an average EPS of -$1.17. EPS for the following year is -$0.87, with 9.0 analysts recommending between -$0.56 and -$1.51.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $36.12M, while the lowest revenue estimate was $2.57M, resulting in an average revenue estimate of $9.29M. In the same quarter a year ago, actual revenue was $2.98M
